Mastodawn

Alteogen Inc. reported a 275% year-on-year surge in 2023 operating profit to 1.148 trillion won, with revenue more than doubling, reflecting robust growth in South Korea's biopharmaceutical sector.
#YonhapInfomax #Alteogen #OperatingProfit #Revenue #Biopharmaceutical #YearOnYearGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103316

Alteogen Posts 275% Surge in 2023 Operating Profit to 114.8 Billion Won

Alteogen Inc. reported a 275% year-on-year surge in 2023 operating profit to 1.148 trillion won, with revenue more than doubling, reflecting robust growth in South Korea's biopharmaceutical sector.

Yonhap Infomax

Yonhap Infomax News Feb 2

Alteogen, a South Korean biopharmaceutical company, reported a 275% year-on-year jump in 2023 operating profit, reaching KRW 114.8 billion.
#YonhapInfomax #Alteogen #OperatingProfit #2023Earnings #Biopharmaceutical #KRW1148Billion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103313

Alteogen Posts 275% Surge in 2023 Operating Profit to KRW 114.8 Billion

Alteogen, a South Korean biopharmaceutical company, reported a 275% year-on-year jump in 2023 operating profit, reaching KRW 114.8 billion.

Yonhap Infomax

Yonhap Infomax News Jan 26

Samsung Bioepis Holdings posts Q4 revenue of 251.7 billion won and an operating loss of 63.6 billion won, reflecting ongoing challenges in the biopharmaceutical sector.
#YonhapInfomax #SamsungBioepisHoldings #Q4Revenue #OperatingLoss #Biopharmaceutical #FinancialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102020

Samsung Bioepis Holdings Reports Q4 Revenue of 251.7 Billion Won and Operating Loss of 63.6 Billion Won

Samsung Bioepis Holdings posts Q4 revenue of 251.7 billion won and an operating loss of 63.6 billion won, reflecting ongoing challenges in the biopharmaceutical sector.

Yonhap Infomax

Yonhap Infomax News Dec 30

Korea Biomedicine Industry Association Chairman Lee Jeong-seok highlighted 2025 as a year of transition and restructuring for the bio industry, projecting significant growth and global competitiveness in the coming year through advances in AI drug development, biosimilars, and CDMO.
#YonhapInfomax #KoreaBiomedicineIndustryAssociation #Biopharmaceutical #AIDrugDevelopment #Biosimilars #CDMO #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97657

Korea Biomedicine Industry Association Chief - 'A Year of Transition and Restructuring—Poised for Leap Forward in the New Year'

Korea Biomedicine Industry Association Chairman Lee Jeong-seok highlighted 2025 as a year of transition and restructuring for the bio industry, projecting significant growth and global competitiveness in the coming year through advances in AI drug development, biosimilars, and CDMO.

Yonhap Infomax

China Business Forum Nov 14

[#TRADESHOW] The 93rd #API #China will be held from November 12–14, 2025, at the #Chongqing #International #Exposition #Center (#CQEXPO). As a #leading #exhibition #event in the #pharmaceutical and #biopharmaceutical #industry, API China #Expo brings together #global and domestic stakeholders for #trade, #networking, and #business #collaboration across the pharmaceutical raw m#aterials and #bioprocessing #sectors. https://cnbusinessforum.com/event/93rd-api-china-2025/